Affiliation:
1. Moscow Medical University "Reaviz"
Abstract
Malignant hyperthermia manifests as hypermetabolism of striated voluntary muscle. Generally, this condition occurs during general anesthesia when inhalational anesthetics and succinylcholine are used. During the malignant hyperthermia attack, the oxygen consumption increases, lactate accumulates, the production of CO2 grows and excessive heat is generated. The crisis of malignant hyperthermia is a dangerous and potentially terminal complication of general anesthesia that requires rapid resolution in the shortest possible time. The only drug that can stop the acute state of malignant hyperthermia – dantrolen, is currently prohibited for import in Russia and is not legalized. Treatment of malignant hyperthermia is extremely difficult for all anesthesiologists in Russia and a great danger for patients with this condition.
Publisher
Reaviz Medical University
Reference19 articles.
1. Richard F. Kaplan, M. D. Postoperative Malignant Hyperthermia: An Analysis of Cases from the North American Malignant Hyperthermia Registry. Anesthesiology. 2008;109 (5):825-829.
2. Riazi S., Kraeva N., Hopkins Ph. Malignant Hyperthermia in the Post-Genomics Era: New Perspectives on the Old Concept. Anesthesiology. 2018;128(1):168-180.
3. Prokopiev G.G., Mikhelson V.A., Agavelyan E.G., Sidorov V.A. Modern views on the syndrome of malignant hyperthermia. Russian Anesthesia Server (In Russ). URL: http://www.mif-ua.com/archive/article/24197.
4. Prokopiev G.G., Mikhelson V.A., Agavelyan E.G., Sidorov V.A. Modern views on the syndrome of malignant hyperthermia. Russian Anesthesia Server (In Russ). URL: http://www.mif-ua.com/archive/article/24197
5. Henry Rosenberg, Mark Davis, Danielle James, Neil Pollock and Kathryn Stowell. Malignant hyperthermia. National Library of Medicine. URL: https://pubmed.ncbi.nlm.nih.gov/17456235/